ABVC BioPharma financials
$1.04−0.95%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | $796.0K | $0.00 | $0.00 | $2.0K | $389.3K | $117.1K | $1.2K | $2.2K | $15.9K |
| Gross profit | $0.00 | $0.00 | — | $796.0K | $0.00 | $0.00 | $2.0K | $389.0K | $117.0K | $928.00 | -$137.0K | -$13.7K |
| Gross margin | — | — | — | 100.0% | — | — | 100.0% | 99.9% | 99.8% | 77.0% | −6329.8% | −86.4% |
| Operating income | -$779.5K | -$1.6M | — | -$1.2M | -$2.3M | -$693.0K | -$704.6K | -$302.3K | -$860.1K | -$2.8M | -$511.8K | -$2.2M |
| Net income | -$736.9K | -$1.6M | — | -$1.2M | -$2.3M | -$842.1K | -$731.6K | -$394.8K | -$942.3K | -$2.8M | -$383.3K | -$3.3M |
| Net margin | — | — | — | −156.6% | — | — | −37211.3% | −101.4% | −804.4% | −235203.2% | −17705.7% | −20885.9% |
| Diluted EPS | $-0.03 | $-0.06 | — | $-0.05 | $-0.13 | $-0.06 | $-0.06 | $-0.03 | $-0.08 | $-0.29 | $-0.06 | $-0.82 |
| EBITDA | -$773.0K | -$1.6M | $5.8K | -$1.2M | -$2.3M | -$686.0K | -$694.1K | -$295.3K | -$846.8K | -$2.8M | -$504.3K | -$2.1M |
| Operating cash flow | -$244.4K | -$894.2K | -$1.4M | -$133.3K | -$894.2K | -$539.8K | -$702.1K | $60.2K | -$211.4K | -$955.8K | -$430.5K | -$1.4M |
| Free cash flow | -$244.4K | -$894.2K | -$1.4M | -$138.7K | -$894.2K | -$539.8K | -$702.1K | $60.2K | -$211.4K | -$955.8K | -$430.5K | -$1.4M |
| Diluted shares | 26.1M | 25.4M | 24.8M | 23.3M | 17.4M | 15.0M | 13.2M | 12.4M | 11.3M | 9.7M | 6.7M | 4.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $31.9K | $140.3K | $681.5K | $192.1K | $388.3K | $152.2K |
| Short-term investments | $62.4K | $62.2K | $64.4K | $65.2K | $65.2K | $65.1K |
| Total debt | $59.5K | $647.7K | $755.5K | $877.9K | $1.1M | $1.6M |
| Total assets | $19.4M | $19.7M | $21.1M | $21.2M | $16.2M | $14.9M |
| Total liabilities | $7.1M | $6.9M | $7.8M | $6.7M | $6.8M | $6.9M |
| Shareholders' equity | $12.3M | $12.8M | $13.3M | $14.5M | $9.5M | $8.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology